The company's principal activity is to develop and market biologically based solutions for the repair and replacement of damaged or inadequate human tissues in different clinical applications. The company's tissue matrix technology removes all cells from the tissue and preserves the tissue without damaging the essential biochemical and structural components necessary for normal tissue regeneration. The products of the company include: alloderm(R) for plastic reconstructive, burn and periodontal procedures; cymetra(tm) for non-surgical correction of soft tissue defects; repliform(tm) for urology and gynecology procedures; cryopreserved allograft skin for use as a temporary wound dressing in the treatment of burns; cymetra (R), a version of alloderm in particulate form; repliform(R) for urogynecologic procedures; graft jacket(R) for orthopedic applications and allocrat f (TM) dbm for bone grafting.
